Ionq, Inc. current report, 30 September 2021

Full document

IonQ, Inc. Form 8-K Summary

Business context and reporting period

Filed October 4, 2021, regarding events completed on September 30, 2021. The filing reports the closing of the business combination between dMY Technology Group III and Legacy IonQ. dMY changed its name to IonQ, Inc., and Legacy IonQ became a wholly owned subsidiary. The transaction also ended the registrant’s status as a shell company. The filing is primarily a transaction and Form 10-type disclosure; it does not present a new quarter-end operating results package for September 30, 2021.

Key financial and capitalization information

  • PIPE financing: 34.5 million shares sold at $10.00 per share for aggregate proceeds of $345.0 million.
  • Redemptions: 950,923 shares redeemed at approximately $10.00 per share, for total redemptions of approximately $9.5 million.
  • Shares outstanding immediately after closing: 192,485,413.
  • Legacy IonQ warrants outstanding: 8,301,202, exercisable at $1.38 per share.
  • Public and other warrants outstanding: 11,500,000, exercisable at $11.50 per share.
  • Existing dMY stockholders held 16.9% of the outstanding common stock on a fully diluted basis immediately after closing.
  • Dividends: None have been paid. Management does not expect to declare cash dividends in the foreseeable future.
  • Revenue, net income or loss, cash flow, operating margins, debt, cash balances, and liquidity metrics: the filing text does not provide clear current-period values. Historical and pro forma financial statements and MD&A are incorporated by reference or filed as exhibits.

Material changes versus the prior comparable period

  • The most significant change was the conversion of dMY from a special purpose acquisition company into the combined operating company, IonQ, Inc.
  • Legacy IonQ equity was converted into common stock using an exchange ratio of 4.048 shares of IonQ common stock for each eligible Legacy IonQ share.
  • IonQ completed the $345.0 million PIPE financing and incurred approximately $9.5 million of shareholder redemptions.
  • The company’s securities began trading under the symbols IONQ and IONQ WS on the New York Stock Exchange, expected to commence October 1, 2021.
  • Ernst & Young LLP replaced WithumSmith+Brown, PC as the independent registered public accounting firm. The filing notes a prior material weakness at dMY related to accounting for warrants and a related restatement.

Guidance, outlook, management commentary, risks, and unusual items

  • The filing does not provide new financial guidance or quantified operating forecasts.
  • Management identifies risks involving realization of merger benefits, competition, growth management, market acceptance, employee retention, intellectual property, customer and regulatory requirements, COVID-19 effects, future capital needs, funding availability, and execution of the business model.
  • The company adopted a 2021 Equity Incentive Plan reserving 26.235 million shares initially, with potential annual increases of up to 5% of the applicable share base through January 1, 2031.
  • The company adopted a 2021 Employee Stock Purchase Plan reserving 5.354 million shares initially, with potential annual increases of up to 1% of the applicable share base through January 1, 2031.
  • Directors and executive officers became eligible for benefits under a change-in-control severance plan and entered into indemnification agreements.
  • The filing states that no material litigation, arbitration, or governmental proceeding was pending against the company or its management team at the filing date.

Important facts for investors to verify

  1. Review Exhibit 99.2 and the incorporated historical financial statements for Legacy IonQ’s revenue, losses, cash flow, cash, and operating trends through June 30, 2021.
  2. Review Exhibit 99.3 for the pro forma capitalization and financial effects of the merger, PIPE financing, and redemptions.
  3. Reconcile the 192.5 million shares outstanding with the 19.8 million outstanding warrants, options, equity-plan reserves, and other potential dilution.
  4. Assess the terms and expiration provisions of the lock-up and registration rights agreements.
  5. Review the warrant accounting material weakness and subsequent remediation disclosures.
  6. Evaluate the absence of dividends, the lack of current debt and liquidity figures in this filing text, and the company’s stated future capital requirements.